New Haven, CT, United States
New Haven, CT, United States

Time filter

Source Type

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim welcomes the updated 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Strategy which now positions a combination of a LAMA (long-acting anticholinergic) and a LABA (long-acting beta2-agonist), as a mainstay treatment for people with Chronic Obstructive Pulmonary Disease (COPD) in GOLD groups B-D.1 This represents a significant change versus previous GOLD guidelines.1 The new Strategy classifies people with COPD by symptoms and history of exacerbations only. It still uses the A, B, C, D system, with each category having its own treatment algorithm supporting a more tailored approach addressing patient needs. For GOLD groups B-D, LAMA/LABA therapy plays a critical, central role in the treatment recommendations.1 "This is a major revision of the GOLD document since 2011 and is a step forward for individualised COPD management. The updated pharmacotherapy recommendations are now based solely on two factors, symptoms and exacerbation history," said Professor Claus Vogelmeier, MD, Chair, GOLD Science Committee, Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Germany. "Our 2017 Global Strategy aims to help people with this chronic but treatable condition by offering holistic treatment guidance that covers pharmacological and non-pharmacological treatments." The 2017 GOLD Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease reflects the latest evidence from published scientific research.1 The added benefits of treatment with a LAMA/LABA beyond the monocomponents alone, and versus LABA/ICS (inhaled corticosteroids) for people with COPD, have been consistently confirmed by a number of randomised, clinical trials.2,3,4,5,6,7,8,9 The evidence includes results from the large-scale, Phase III TOviTO® clinical trial programme. The data also demonstrate Spiolto® Respimat® (tiotropium+olodaterol) provides significant improvements in patient outcomes over Spiriva® Respimat® (tiotropium), right from the initial stages when people with COPD need maintenance therapy.6,7,8,10,11 The new GOLD Strategy provides clear guidance on when, and in which patients, ICS can be added or withdrawn.1 All COPD patients should be treated with therapies that optimise lung function first. Only those who have ≥2 exacerbations per year or ≥1 exacerbation leading to hospital admission may be considered for an ICS-containing therapy after LAMA/LABA. In addition, the new GOLD Strategy suggests that ICS therapy may be withdrawn safely in people with COPD who are in GOLD group D and stable, by using a LAMA/LABA regimen.1 Several studies, including the Withdrawal of Inhaled Steroids During Optimised bronchodilator Management (WISDOM) study,12,13,14,15 have helped inform the de-escalation path. “Boehringer Ingelheim is pleased that our extensive, ongoing clinical trial programme in COPD has contributed to the latest GOLD Strategy. We are committed to continuing research into the optimal management of COPD to achieve the best possible outcomes for people with COPD,” said Dr William Mezzanotte, MD MPH, Vice President and Head of Respiratory Medicine at Boehringer Ingelheim. COPD is a serious but manageable lung disease, which is estimated to affect 210 million people worldwide.16 Total deaths from COPD are projected to increase by more than 30 percent in the next 10 years; COPD is predicted to become the third leading cause of death globally by 2030.17 Once daily Spiolto® Respimat® is Boehringer Ingelheim’s advance in COPD maintenance treatment, and has been approved in more than 50 countries worldwide. For ‘Notes to Editors’ and ‘References’ please visit: http://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-welcomes-central-role-lamalaba-therapy-within-2017-gold-strategy


INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved tiotropium Respimat® (marketed as SPIRIVA® Respimat®) for the long-term, once-daily maintenance treatment of people with asthma aged 6 years and older who continue to experience symptoms despite their other maintenance therapy – usually either inhaled corticosteroid (ICS) alone, or a combination of inhaled corticosteroids/long-acting beta agonists (ICS/LABA).1 This approval reflects the comprehensive tiotropium Respimat® paediatric clinical trial programme, involving 905 children aged 6-11 years, conducted by Boehringer Ingelheim.2,3,4 Tiotropium Respimat® is part of a class of medicines called long-acting muscarinic antagonists (LAMA) and is the only one of its kind approved for asthma. It works differently from other treatment options by complementing other maintenance therapies (usually ICS/LABA) to open the airways, which helps people breathe better and reduces asthma attacks, also known as exacerbations. “This FDA approval expands the US indication for tiotropium Respimat® to a broad range of patients, including children, adolescents and adults in the US who may suffer from symptomatic asthma despite taking other maintenance therapies,” said Dr William Mezzanotte, Vice President and Head of Respiratory Medicine at Boehringer Ingelheim. “The expansive paediatric programme within the comprehensive UniTinA-asthma® clinical trial programme, reflects the ongoing commitment of Boehringer Ingelheim to providing innovative solutions for children and adults living with asthma and other serious respiratory diseases.” In the comprehensive, large-scale UniTinA-asthma® clinical trial programme, tiotropium Respimat® demonstrated proven efficacy and safety as an add-on therapy for children, adolescents and adults with asthma.1,5,6,7,8,9,10,11,12,13 Tiotropium Respimat® is delivered via Respimat®, the only inhaler that actively* delivers a propellant-free mist, meaning a person just needs to take a slow deep breath in for the medication to go deep into the lungs.14,15,16,17,18,19,20 Previously, in September 2015, tiotropium Respimat® was approved in the US for the long-term, once-daily, prescription maintenance treatment of asthma in people aged 12 and older.1 Tiotropium Respimat® was approved in the EU in 2014 as an add-on therapy for adults (aged 18 and older) with asthma. For more information please visit http://www.boehringer-ingelheim.com/press-release/ASTHMA-FDA-Expanded_Approval_of_Tiotropium_Respimat® This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products varies from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business. SPIRIVA® Respimat® is currently NOT APPROVED for use in children and adolescents under 18 years of age in the EU. SPIRIVA® Respimat® has been approved for use in asthma in over 50 countries, including in the EU, U.S. and Japan. The label varies by country. Please refer to the local product information. * Respimat® delivers a metered dose of medication in a mist at the push of a button not requiring the force from the patient’s inhalation


Kerwin E.M.,Southern Research Institute | Scott-Wilson C.,Glaxosmithkline | Sanford L.,Glaxosmithkline | Rennard S.,University of Nebraska at Omaha | And 3 more authors.
Respiratory Medicine | Year: 2013

Background: Fluticasone furoate (FF)/vilanterol (VI) is a novel once-daily inhaled corticosteroid/long-acting β2-agonist combination therapy for COPD. We aimed to assess the efficacy and safety of two strengths of FF/VI (100/25 μg; 50/25 μg) vs. individual components (FF 100 μg, VI 25 μg) and placebo over 24 weeks. Methods: Multicentre, randomised, placebo-controlled, double-blind, parallel-group study of patients (N = 1030) with moderate-to-severe COPD. All medication was administered once daily in the morning. Co-primary efficacy endpoints were: (1) weighted mean (wm) FEV 1 (0-4 h post-dose on day 168) to assess acute lung function effects; and (2) trough FEV1 (23-24 h post-dose on day 169) to assess long-lasting effects. Symptom-related outcomes were analysed and adverse events (AEs) assessed. Results: Main findings were: (1) the combination of FF/VI at a strength of 100/25 μg significantly (p < 0.001) improved wm FEV 1 (173 ml) and trough FEV1 (115 ml) vs. placebo. Similar effects were observed with FF/VI 50/25 μg; (2) no significant difference was seen between FF/VI 100/25 μg and VI 25 μg for trough FEV1 (48 ml, p = 0.082), while an effect was observed between FF/VI 100/25 μg and FF 100 μg for wm FEV1 (120 ml, p < 0.001); (3) VI 25 μg over 24 weeks improved lung function vs. placebo significantly for wm FEV1 (103 ml, p < 0.001) and trough FEV1 (67 ml, p = 0.017); and (4) no safety signal was observed. Conclusions: In subjects with moderate-to-severe COPD, FF/VI 100/25 μg provides rapid and significant sustained bronchodilation at 24 weeks. Lung function is improved to a similar extent with FF/VI 50/25 μg and to a somewhat lesser extent with VI 25 μg. All treatments were well tolerated. GSK study number: HZC112206. ClinicalTrials.gov: NCT01053988.© 2012 Elsevier Ltd. All rights reserved.


News Article | December 7, 2015
Site: www.biosciencetechnology.com

Whole Genome Sequencing is a faster, cheaper and more effective way of diagnosing tuberculosis says a new study published in the journal Lancet Respiratory Medicine. Dr. Louise Pankhurst of the University of Oxford and a team of worldwide collaborators including Public Health England utilised innovative DNA technology to diagnose cases of tuberculosis (TB) up to eight times faster than traditional methods. While Whole Genome Sequencing has been previously used in TB research studies, this is the first time the technology was applied in real world scenarios. The researchers at Oxford's John Radcliffe Hospital were able to detect presence of TB and whether it was resistant to commonly used antibiotics within one week – up to eight times faster than utilising traditional diagnosis methods. In addition to facilitating faster and more targeted treatment of people with TB, the speedy diagnosis also meant the scientists were able to detect and respond to potential outbreaks as they happen. The innovative technology also proved more cost effective, at an average cost of £481 per positive case, compared to £517 per case using current technologies. The stunning results of this trial have implications for TB prevention in the UK. It was funded by the Health Innovation Challenge Fund (HIC Fund) and supported by the NIHR Oxford Biomedical Research Centre and the NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance. The new technique will be adopted by Public Health England (PHE) and is expected to reduce transmission of TB. Tuberculosis is a major part of PHE's strategy for infectious diseases due to some increases in incidence and emergence of multi-drug resistant infections. PHE is also working with Genomics England as part of the 100,000 Genomes Project to further understanding of why some people develop severe reactions to infections. Lead author Dr. Louise Pankhurst, University of Oxford, said: 'This is a really exciting time to be working in infectious disease research. The UK is poised to become the first country in the world to replace traditional tuberculosis diagnosis with whole genome sequencing. Our study has shown how this will dramatically speed up the time taken to diagnose TB, helping patients be placed on the most effective treatment as soon as possible and reducing the risk of disease transmission.' Professor Derrick Crook, Director of the Public Health England National Infections Service said: 'This ground-breaking research provides a roadmap for faster, cheaper and more effective diagnosis of TB, and is a crucial step in Public Health England’s goal of eliminating TB as a public health problem in England. 'This marks a significant milestone in the way we tackle TB, yet things are going to get better as whole genome sequencing technology is rapidly becoming much faster and less expensive and will ultimately inform the way we deal routinely with all infectious disease diagnosis.'


News Article | December 9, 2016
Site: globenewswire.com

MELBOURNE, Australia, Dec. 09, 2016 (GLOBE NEWSWIRE) -- Adherium Limited (ASX:ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announces that some of Europe’s most prestigious clinical opinion leaders have chosen Adherium’s Smartinhaler™ for the myAirCoach programme, part of the European Union’s Horizon 2020 Framework for Research and Innovation. The myAirCoach programme is being funded through the Horizon 2020 framework which is the largest EU Research and Innovation programme ever established with nearly €80 billion of funding available over 7 years (2014 to 2020). The purpose of the myAirCoach programme is to establish whether home monitoring and mobile health (mHealth) systems can be used to predict asthma control and the occurrence of asthma exacerbations. One of the main goals of the project is to help patients manage their health through user-friendly tools that will increase awareness of their clinical state as well as the adherence and effectiveness of the medical treatment they follow. The impact of the myAirCoach programme is expected to set the basis for the widespread adoption of sensor-based self-management systems across the spectrum of respiratory diseases. (Source: http://www.myaircoach.eu/myaircoach/content/what-myaircoach-project) Smartinhaler™ is already proven to reduce hospitalisation as demonstrated in the results of the year-long STAAR study, recently published online in the prestigious peer-reviewed medical journal Thorax [1]. The study revealed a significant reduction in hospital admissions over the course of 12 months as well as substantial other health and quality of life benefits for patients using Smartinhaler™. The data from the STAAR study builds on a study published in January 2015 in The Lancet Respiratory Medicine [2] which showed the use of the Smartinhaler™ platform increased adherence to preventative medication by 180% and reduced use of reliever medication by 45%. “Successful disease management and prevention is only truly achieved by understanding the real-world complexity of our lives. The best way to do that is through rich data collected in the real world. By providing our innovative solutions to people with asthma, we can help people take the right medicine, at the right dose, at the right time and in the right way,” said Garth Sutherland, Founder & Group CEO of Adherium. “The myAirCoach programme is a leading initiative assessing the impact that digital health solutions, such as Smartinhaler™, can have on patients in a real-world setting. It is a major international project, funded by the prestigious European Union Horizon 2020 framework.” Participating organisations in the myAirCoach project include: Imperial College London, University of Manchester and Leiden University Medical Center. The project is anticipated to run for the next 12 months. Dr. Omar Usmani, Reader in Respiratory Medicine & Consultant Physician, National Heart and Lung Institute, Imperial College London and Royal Brompton Hospital, said; “The myAirCoach programme will help asthma sufferers to manage their health through user-friendly tools that will increase awareness of their clinical state as well as their adherence and the effectiveness of medical treatment they follow.” Professor Fan Chung, Professor of Respiratory Medicine and Head of Experimental Studies Medicine, National Heart and Lung Institute, Imperial College London and Royal Brompton Hospital, commented; “People with asthma are more likely to miss school or work and experience reduced quality of life.  We are excited about the collaboration between Adherium and myAirCoach which is expected to set the basis for the widespread adoption of sensor-based self-management systems across the spectrum of respiratory diseases.” Adherium will be supplying a range of products to the programme via three key centres, including devices for inhaled medications manufactured by AstraZeneca and GSK: The project is coordinated by the Centre for Research and Technology Hellas (CERTH), Thessaloniki, Greece and is supported by a group of asthma patients acting as advisors.  Other participating organisations in the myAirCoach project include: University of Patras, Allertec Hellas SA, IHP Microelectronics, ZorgGemak (MedVision 360BV), European Federation of Asthma & Allergy Associations, Cnet Svenska AB, Circassia and Asthma UK. More information on myAirCoach can be found at the project’s website http://www.myaircoach.eu/myaircoach/ [1] Published online: Thorax doi:10.1136/thoraxjnl-2015-208171 [2] Chan AHY, Stewart AWS, Harrison J, Camargo C, Black PN, Mitchell EA. The effect of an inhaler with ringtones on asthma control and school attendance in children. Lancet Respir Med. 2015;3:210-219 Adherium (ASX:ADR) is an Australian Securities Exchange listed company which develops, manufactures and supplies digital health technologies which address sub-optimal medication use and improve health outcomes in chronic disease. Adherium operates globally from bases in the USA, Europe and Australasia. Adherium is a provider of digital health solutions to patients, pharmaceutical companies, healthcare providers and contract research organizations. The Company’s proprietary Smartinhaler™ platform has been independently proven to improve medication adherence and health outcomes for patients with chronic respiratory disease. Adherium has the broadest range of "smart" medication sensors for respiratory medications globally. The Smartinhaler™ platform has so far been used in more than 65 projects (clinical, device validation or other) and has been referenced in 56 peer reviewed journal articles. Clinical outcomes data has proven that the Smartinhaler™ platform can improve adherence by up to 59% in adults and 180% in children and reduce severe episodes by 60% in adults, leading to improved quality-of-life and demonstrating a substantial gain over current best practice treatment. The Company has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software, which allows it to sell these devices into international markets.


News Article | November 24, 2015
Site: motherboard.vice.com

One night while watching TV, Chris Kunkel decided to kill himself. “Out of nowhere, it just came over me,” Kunkel told me over the phone. He found a bottle of Tylenol PM in the medicine cabinet, swallowed the contents, and put himself to bed. Kunkel was home alone; his wife and two kids were out of town visiting family, but he was on call for work as an army IT specialist and had to stay behind. He had a great life, and no history of depression or mental illness of any kind. The dark thought simply bloomed in his mind, as natural as any other. “It was like thinking, ‘I’m going to go outside for a smoke,’ or ‘I’m going to go to the bathroom,’” Kunkel said. “Except it was: ‘I’m going to kill myself.’” Luckily, Kunkel’s wife arrived home shortly after he downed the fistful of pills. She had decided to come home early to surprise him and found him unconscious next to the empty bottle. She called 911. In the hospital the next morning, Kunkel said he struggled to piece together the events of the night before. “It took awhile for the cobwebs to clear and for me to realize what had happened, and it was tough to try to explain,” Kunkel said. “Really it wasn’t until we got home that we realized that the Chantix probably played a major part.” Kunkel had recently started taking Chantix, a prescription drug intended to help people quit smoking. It worked: Kunkel did quit smoking. He went from a seven-year, pack-a-day habit to cold turkey just 10 days after his first pill. Ten days after that, he tried to kill himself. His story isn’t unique. Since entering the market in 2006, hundreds of Chantix users have reported a laundry list of disturbing effects ranging from intense nightmares, to amnesia, to suicidal (and even homicidal) thoughts and behavior. There were enough reports that the Food and Drug Administration ordered Pfizer, the maker of Chantix, to include a black-box warning label, the strictest possible labeling requirement. Yet dozens of scientific studies have failed to find any link between Chantix and adverse psychiatric effects. These are not just Pfizer’s in-house trials, but independent double-blind, placebo-controlled studies, focused observational studies, and sweeping meta-analyses. These are studies published in illustrious journals like The Lancet and the BMJ. While some of these results come from researchers with ties to Pfizer, many do not, and all of the studies I reviewed came to the same consensus: there’s no evidence Chantix is linked to adverse psychiatric events. How can there be such a gulf between what the science is indicating and what the population is reporting? Testimonies from former Chantix users like Kunkel make it difficult to come to any conclusion other than the one he came to: that Chantix caused him to have suicidal thoughts. But a review of the scientific literature has the exact opposite effect: one can’t help but conclude that something else is causing these people to feel like they’re losing control. The truth is difficult to pin down, and it’s made Chantix a unique case study in how we view prescription drugs, scientific proof, and addiction. And it raises a sobering question: When it comes to risk, can we ever be truly sure that a drug is safe? “That’s where the trouble really started.” Ten years ago, on a Wednesday in November, Pfizer filed an application with the FDA for approval of a new drug to help people quit smoking. Included in that application was a stack of pre-market trials Pfizer had completed, testing the drug on more than 4,500 patients, many for a full year. The worst side effects that were reported were intense, vivid dreams and some nausea, but no serious psychiatric events emerged. “In addition to being efficacious, varenicline appeared to be well tolerated by most participants,” read a report based on these clinical trials published in the Journal of the American Medical Association the summer after the FDA approved Chantix. “Nausea, the most common complaint, was reported as being mostly mild to moderate in severity and rarely resulted in discontinuation of study medication. [...] Varenicline may represent an advance in the treatment of tobacco dependence.” And the drug proved very effective in helping people kick their tobacco habits: after one year, 23 percent of participants were still tobacco-free, and hadn’t taken a single puff since quitting, even though they were only given the drug for the first twelve weeks. Compared to other smoking cessation treatments—nicotine patches and gum, for example, have about a 6 percent success rate—this was remarkable. Varenicline, the drug Pfizer would market as Chantix, is a combination of nicotinic partial agonist and antagonist. Agonist means it stimulate receptors in the brain, and antagonist means it blocks those receptors from being stimulated by other chemicals. Chantix does both. When a smoker takes a puff of a cigarette, the nicotine in the smoke is absorbed through the lungs into the bloodstream, hitching a ride to the brain. The nicotine binds to nicotonic receptors in the brain, which causes a release of dopamine, giving the brain a feeling of reward. It’s a short-lived little high that helps contribute to the addictive qualities of tobacco. Varenicline works by binding to those receptors before the nicotine can get there, which does two things to help someone quit smoking. First, it causes the brain to release a little bit of dopamine (about 40 percent of what nicotine would, that’s the “partial” part of a partial agonist), which helps curb the craving for a cigarette—your brain already got its dopamine reward, so it’s not seeking it from another source. Second, it blocks nicotine from being able to bind to those receptors (that’s the antagonist function), so even if you do smoke, the nicotine doesn’t have the same effect. In May, 2006, the FDA gave the green light to start marketing Chantix. “Initially, there was tremendous uptake. There was just a huge, pent-up demand of these drugs,” said Dr. Frank T. Leone, the director of comprehensive smoking treatment programs at the University of Pennsylvania’s Abramson Cancer Center. (Leone has no affiliation to Pfizer and his research, which focuses on smoking cessation tactics and nicotine addiction, has never been funded by Pfizer.) Varenicline is not the only smoking cessation drug on the market (Zyban, or bupropion, is another popular choice that’s been around since 1997) but with a slightly higher success rate than its predecessor, it quickly became one of the most frequently prescribed drugs in the world. Since it came on the market in 2006, Chantix has been prescribed to more than 11 million unique patients in the US and more than 22 million unique patients globally, according to Pfizer. Leone said Chantix followed a similar arc to Zyban, with an initial burst of popularity that later fizzled out. “The sales would go through the roof, and then shortly after, sales would taper off when comments about weird side effects emerged,” Leone said. For Chantix, the honeymoon ended a little more than a year after the drug hit the market. It started with a smattering of online posts from users claiming they were having suicidal thoughts after taking the drug. It hit a climax with the death of Carter Albrecht. Albrecht was a musician best known for his work as a keyboardist and guitarist for the New Bohemians. In August 2007, Albrecht started taking Chantix. A week later, after a night of drinking, he started behaving erratically, yelling at and attacking his long-time girlfriend. When she locked him out of the house, he went to the neighbor’s and began yelling at the house from the yard. The neighbor fired a “warning shot” through the door, which struck Albrecht in the head and killed him. Albrecht’s girlfriend and family publicly blamed Chantix for his sudden change in behavior and subsequent death. His parents even tried to sue Pfizer. After Albrecht’s death, the FDA began receiving hundreds of reports through its adverse events reporting system, a kind of hotline where anyone can report side effects for any drug. By November, 2007, the reports had totaled enough that the FDA alerted the public, launched an investigation, and ordered Pfizer to update its label. In 2009, as the reports from the public continued to mount—hundreds of adverse effects have been reported each year since Albrecht’s death—the FDA ordered Pfizer to add a black box warning. A black box warning is the most severe labeling requirement the FDA has, and is “designed to call attention to serious or life-threatening risks,” according to the agency. The warning Pfizer is required to use on all of its Chantix literature, including a large disclaimer on its website, includes pretty ominous language warning patients that “some people have had changes in behavior, hostility, agitation, depressed mood, suicidal thoughts or actions while using Chantix to help them quit smoking.” Chantix's alleged dark side was a topical enough to warrant a Saturday Night Live skit. At the same time as it issued the black box warning, the FDA ordered Pfizer to do trials specifically looking for evidence of neuropsychiatric adverse events, and how the drug affects people with existing mental health issues. “I never thought that it would give me the results that it did, that it would throw my life into complete disarray,” said Derek De Koff, a journalist who penned a feature for New York magazine in early 2008 on his experience using Chantix. De Koff wrote that he had bizarre, vivid nightmares, that he felt tired, paranoid, and depressed. He wrote that he contemplated suicide without even really grasping that that’s what he was doing. “Maybe I should just go downstairs and leap in front of a tour bus,” De Koff wrote, recalling his experience. “Or launch my head through the computer screen. All this seemed logical, but also weirdly funny, even at the time: I could see how crazy these impulses were, I could recognize them as suicidal clichés. But I couldn’t make them go away.” De Koff still believes Chantix was responsible for his dark thoughts and feelings—he hasn’t experienced any since going off of the drug seven years ago. In his story, he questioned the quality of the premarket trials of varenicline, which were limited by only including people who had no history of certain illnesses including depression and alcohol and drug abuse. De Koff told me he still thinks the initial results were flawed because of this limitation. “Somebody who smokes a lot, there’s a very good chance they drink as well and there were no studies as to how this drug would impact somebody who was drinking,” De Koff said. “A lot of the stories come from people who were on Chantix and drinking. It’s a dangerous mix, or it was a dangerous mix for me. That’s where the trouble really started.” When the concern about Chantix’s possible dark side first started to build, the only data we had to rely on about varenicline were these consumer reports and Pfizer’s few premarket trials. There wasn’t enough information to say with any certainty whether Chantix was causing these sometimes terrifying symptoms. But we’ve come a long way since then. The FDA’s adverse effects reporting system is a useful tool for the agency. It’s a quick and easy way for patients, doctors, and families to report any potential side effects. If reports start to show a pattern, it’s usually a clue that more scientific research needs to be conducted. The reports on Chantix show a definite pattern. From January 1 of this year to October 16, the Food and Drug Administration received 1,811 reports of adverse effects attributed to varenicline, according to documents obtained by Motherboard through a Freedom of Information Act request. Of those, 98 included suicidal thoughts, 18 reported a completed suicide, and two reported a homicide. Some of the reports filed through the FDA's adverse event reporting system. It’s disturbing to read through hundreds of cold, clinical reports dotted with terms like “nightmare,” “hallucination, auditory,” and “completed suicide.” But it’s important to view these reports in context: these are anecdotal, unproven associations. They can’t be taken as proof of a causal relationship. Just as an anti-vaxxer could report autism as a side-effect of the MMR vaccine, anyone can report any symptom and attribute it to Chantix. “It’s completely uncontrolled and anyone can call in and say ‘I had this effect while taking Chantix,’” said Suzanne Colby, a tobacco researcher and the associate director of the center for alcohol and addiction studies at Brown University. Colby has no affiliation with Pfizer and none of her research has ever been funded by Pfizer (nor any other drug company, she noted). “When you don’t see these effects in the context of controlled trials but you do see it reported in this type of database, it makes me think it’s not the Chantix," Colby said. "As a scientist, that’s my conclusion.” Though the scientific literature has shown Chantix can cause abnormal dreams (the kind of intense nightmares often reported by users), this has been a long-known side effect, one that was evident in Pfizer’s original drug application. When it comes to the reported paranoia, dark thoughts, and suicide attempts linked to Chantix, there are dozens of studies that fail to show a connection. A massive study published in last month’s issue of The Lancet: Respiratory Medicine pulled data from the National Health Service in the UK to look for evidence of a link between Chantix and neuropsychiatric risks as well as cardiovascular risks. Looking at more than 160,000 patients, the researchers found no increased risk of neuropsychiatric events when compared to bupropion (the other popular stop smoking drug) or nicotine replacement therapy (things like the patch and gum). (Two out of the six study authors have received grants from Pfizer, though those grants were not used on this study.) Earlier this year, a review of the current scientific literature on varenicline was published in Nicotine & Tobacco Research. The review was written by Dr. John Hughes, who has previously received funding from Pfizer, but is also considered one of the foremost experts on nicotine. Hughes looked at 46 studies, 41 of which were not funded by Pfizer, specifically looking at suicidal outcomes. He found the studies consistently showed no increased risk of suicide with varenicline, and in the handful where there was an increased risk, it was very low. And if the Pfizer affiliations are making you suspicious, there are plenty of examples of completely independent studies finding the same results. A study published in the February issue of BMJ reviewed 39 trials involving 5,817 patients who were taking Chantix and 4,944 patients taking placebos. The researchers found “no increased risk of suicide or attempted suicide, suicidal ideation, depression, or death in individuals treated with varenicline.” None of the study authors have any affiliation with Pfizer or have received any funding from Pfizer. A study from 2013, also with no ties to Pfizer, looked at 120,000 patients undergoing some form of smoking cessation treatment and found no evidence of association between varenicline and an increased risk of suicide or depression. There are also studies that focus on specific groups, like people with schizophrenia or bipolar disorder. Even with pre-existing neuropsychiatric issues, researchers found no risk of adverse effects linked to Chantix. Colby suspects there are a number of factors that could be leading to the reports of negative side effects, ranging from fodder for courtroom defenses to the very real side effects of nicotine withdrawal. The fact is that Chantix is a pretty effective stop-smoking aid, so many people who report scary side effects have recently kicked two or three-pack-a-day habits, and that takes a toll on the brain, Colby said. “The most common things are cravings, irritability, frustration, sleep disturbance, difficulty concentrating, negative affect generally, depression,” Colby said. “For people who have various forms of mental illness, maybe those are exacerbated. These things that happen very idiosyncratically, how do we know that it’s the Chantix versus something that would have happened anyway? The only way to answer that question is with clinical trials.” It’s worth noting that Pfizer’s fingerprints are littered throughout the scientific literature—it’s a bit of a hazard with this field of study, in general. Many studies have one or more authors with some kinds of ties to the company, ranging from accepting research grants from Pfizer to testifying as expert witnesses for Pfizer in court. This doesn’t mean the studies are invalid, but it does show Pfizer clearly is investing a lot of money into studying, and possibly exonerating, Chantix. And the company's motivations are worth considering. Just weeks after Albrecht’s death, lawyers began advertising for lawsuits. These rounds of early suits have cost Pfizer millions of dollars in settlements. By February of 2013, the company had settled most of its claims at a total cost of $273 million, according to SEC filings. It estimated it would need to spend another $15 million on the outstanding cases, and a class action suit in Canada is still pending, according to this year’s filing. “Pfizer believes there is no reliable scientific evidence establishing a causal relationship between Chantix and serious neuropsychiatric events,” said Steven Danehy, a spokesperson for Pfizer, in an email. “Smoking is one of the leading preventable causes of death in the world. Stopping smoking is one of the most important steps a person can take to improve their health, and the benefits of quitting are immediate and substantial. However, many people who want to quit struggle to do so without help. The risks of Chantix should be weighed against the benefits of its use.” Pfizer is also just months away from publishing the results of a massive clinical trial looking at the effects of varenicline specifically on patients who have a history of psychiatric disorders, an undertaking requested by the FDA as the agency considers rewording or lifting the black-box warning requirement. “You have a tricky conundrum: you want to be cautious and provide every possible piece of info to the public to help them make a decision, but on the other hand you don’t want to put people off using what is probably the most effective stop smoking method we’ve got,” said Robert West, a professor of health psychology and the director of tobacco studies at University College London. West was a co-author on the Lancet study and has received grants from Pfizer. “You can’t discount the observational data [from consumer reports,]” West continued. “There’s something going on and we don’t know what it is, but when you have a drug taken by millions of people, the laws of chance for this kind of thing are always against you.” Cigarette smoking causes close to half a million deaths in the US annually, according to the Centers for Disease Control and Prevention. Life expectancy for smokers is ten years shorter than nonsmokers, and if you can quit smoking before you turn 40, your chance of dying from a smoking-related disease drops by 90 percent. With a higher effectiveness than any other smoking cessation treatment, Chantix can quite literally extend people’s lives. But the reams of testimonies from patients who have suffered scary, even life-threatening, side effects from the drug online and in the media, combined with the alarming warnings issued by the FDA, could make anyone hesitant to try, and stick with, the drug. And there’s another factor at play. Despite the clear health benefits of quitting smoking, people don’t view Chantix or drugs like it as “life-saving.” We accept the truly awful side effects of treatments like chemotherapy (which include vomiting, mouth sores, diarrhea, and burning sensations) because we know the trade off is the chance for a longer life. But when the benefits of a drug are delayed by years or even decades, like with a smoking cessation aid, we’re less willing to endure any possible negative side effects in the short term. “If we had done this study with anything other than Chantix, I think people would have said ‘yeah, absolutely, fine. No evidence of an effect, we’ll move on. That’s good news,’” West told me via Skype. “But with Chantix, that idea is there." There are also pervasive cultural ideas that might make someone weigh the risks of Chantix more strongly than the risks of continuing to smoke. The public generally perceives addiction as a shortcoming, something you should just be able to overcome on your own. Why would you risk feeling suicidal to fix a problem you really ought to be able to just solve on your own? “It’s a common perspective in smokers and particularly in smokers with substance use disorders,” Colby told me. “And adolescents and young adults in particular are very unlikely to take a pharmacotherapy to quit smoking, because they don’t really perceive smoking as something that should require treatment to quit.” And there’s the issue with proof. Can we ever truly say a drug is 100 percent safe? West said once an idea that a drug is dangerous has made its way into the public consciousness, the burden of proof becomes much higher. Instead of looking for evidence of a relationship between Chantix and negative effects, the researcher is tasked with seeking out evidence that there isn’t a relationship. "It’s probably not related [to neuropsychiatric effects], but the key is in the ‘probably,’ because you can’t say definitely,” West said. “How do you prove a negative? You can’t.” The FDA assesses drug risks all the time. If it thinks there is enough evidence that a drug causes more harm than good, it pulls it from the market (and that’s if a drug company hasn’t already pulled it). The FDA’s label requirements on Chantix aren’t proof that the drug causes people to come undone, it’s just relaying the information we have: there have been reports of serious neuropsychiatric adverse effects. Thousands of reports. And at the end of the day, there’s no way to know for sure that a drug is 100 percent safe for every person. As for Kunkel? He stopped taking Chantix and started smoking again as soon as he got home from the hospital, but recently quit by switching to vaping. He told me he hasn't had any issues with depression or suicidal thoughts since he stopped taking Chantix. “I truly believe it just depends on the person, ” Kunkel said. “Everyone’s built differently.” Lit Up is a series about drugs and drug-like substances and practices. Follow along here.


Turner A.M.,University of Birmingham | Turner A.M.,Birmingham Heartlands Hospital | Tamasi L.,Semmelweis University | Schleich F.,Respiratory Medicine | And 4 more authors.
European Respiratory Review | Year: 2015

As knowledge of airways disease has grown, it has become apparent that neither chronic obstructive pulmonary disease (COPD) nor asthma is a simple, easily defined disease. In the past, treatment options for both diseases were limited; thus, there was less need to define subgroups. As treatment options have grown, so has our need to predict who will respond to new drugs. To date, identifying subgroups has been largely reported by detailed clinical characterisation or differences in pathobiology. These subgroups are commonly called “phenotypes”; however, the problem of defining what constitutes a phenotype, whether this should include comorbid diseases and how to handle changes over time has led to the term being used loosely. In this review, we describe subgroups of COPD and asthma patients whose clinical characteristics we believe have therapeutic or major prognostic implications specific to the lung, and whether these subgroups are constant over time. Finally, we will discuss whether the subgroups we describe are common to both asthma and COPD, and give some examples of how treatment might be tailored in patients where the subgroup is clear, but the label of asthma or COPD is not. © ERS 2015.


Vanstone M.B.,Yale University | Egan M.E.,Respiratory Medicine | Zhang J.H.,Veterans Administration Cooperative Studies Program Coordinating Center | Carpenter T.O.,Yale University
Pediatric Pulmonology | Year: 2015

Objective To identify effects of vitamin D status, as defined by circulating 25-hydroxyvitamin D (25-OHD) levels on the annual frequency of pulmonary exacerbations (Pex) and hospitalizations, on standard measures of pulmonary function, and to identify determinants of 25-OHD levels in pediatric patients with cystic fibrosis (CF). Hypothesis Higher levels of serum 25-OHD would be associated with fewer Pex and hospitalizations, and improved lung function based on pulmonary function tests (PFTs). Study design Retrospective chart review of 53 pediatric patients from January 2011 to December 2011. Significant relationships were examined using linear and logistic regression analyses. Patient Selection Patients ages 5 through 22 years followed at the CF Care Center and Clinic at Yale-New Haven Hospital, New Haven, CT., who had at least four clinic visits and at least one 25-OHD measurement between January 1, 2011 and December 31, 2011. Results Serum 25-OHD level and gender were strong independent determinants of the annual number of Pex (P-<-0.01, with lower 25-OHD level and female gender associated with Pex). There was a significant influence of gender (P-<-0.05) and a near-significant influence of serum 25-OHD (P-<-0.08) on hospitalization rate. There was no effect of 25-OHD levels on PFTs. Other candidate factors (age, season, gender, pancreatic sufficiency, or severity of genetic mutation) did not significantly effect 25-OHD level. Conclusions The annual number of Pex in pediatric CF patients is significantly associated with 25-OHD levels and gender, raising the consideration that maintaining vitamin D sufficiency may lead to decreased incidence of Pex and hospitalizations requiring antibiotic therapy. © 2015 Wiley Periodicals, Inc.


Vaes A.W.,Program Development Center | Wouters E.F.M.,Program Development Center | Franssen F.M.E.,Program Development Center | Uszko-Lencer N.H.M.K.,Cardiology | And 6 more authors.
Chest | Year: 2011

Background: Patients with COPD generally have a poor peak aerobic capacity and, therefore, may experience more inconvenience during domestic activities of daily life (ADLs). Yet, task-related oxygen uptake and symptom perception during ADLs have been studied rarely in COPD. Therefore, it remains unknown whether and to what extent differences may exist in task-related oxygen uptake and symptom perception during ADLs in patients with COPD after stratifi cation for sex; GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage; Medical Research Council (MRC) dyspnea grade; or score on the BMI, obstruction, dyspnea, exercise capacity (BODE) index. Methods: Ninety-seven patients with COPD and 20 healthy elderly subjects performed the following fi ve self-paced domestic ADLs with 4-min rest intervals: putting on socks, shoes, and vest; folding eight towels; putting away groceries; washing four dishes, cups, and saucers; and sweeping the fl oor for 4 min. Task-related oxygen uptake was assessed using an Oxycon Mobile device, whereas Borg scores were used to assess task-related dyspnea and fatigue. Results: Patients with COPD used a signifi cantly higher proportion of their peak aerobic capacity and ventilation to perform ADLs than did the healthy subjects, accompanied by higher taskrelated Borg dyspnea scores. Patients with GOLD stage IV, MRC dyspnea grade 5, or BODE score ≥ 6 points had the highest task-related oxygen uptake and dyspnea perception during the performance of domestic ADLs. Results showed no sex-related differences. Conclusion: Patients with COPD experience a relatively high metabolic load and symptom perception during the performance of ADLs that is not the same as seen in their healthy peers, particularly in patients with GOLD stage IV, MRC dyspnea grade 5, or BODE score ≥ 6 points. © 2011 American College of Chest Physicians.


News Article | November 28, 2016
Site: www.prweb.com

Doctors in Scotland are working to improve mesothelioma diagnosis by creating a list of biomarkers to identify the disease. Surviving Mesothelioma has just posted an article on the newly-announced study. Click here to read it now. The trial will involve up to 120 pleural mesothelioma patients as well as 480 people with other pleural diseases and 109 asbestos-exposed people. Everyone involved in the trial will submit a blood sample and undergo a clinical exam. “Blood levels will be compared with paired pleural fluid levels and malignant pleural mesothelioma tumor volume (using MRI) in a nested substudy,” explains researcher Selina Tsim of the Department of Respiratory Medicine at Queen Elizabeth University Hospital in Glasgow. The trial announced in the British Medical Journal’s open access online-only journal BMJ Open will be carried out at 22 recruiting centers across Scotland. “There is a tremendous need for more reliable biomarkers for mesothelioma diagnosis and prognosis, especially since diagnostic procedures like thoracoscopy are not available everywhere and are expensive,” says Alex Strauss, Managing Editor of Surviving Mesothelioma. Learn more about the new biomarker study, including some of the biomarkers researchers will be looking at closely, in the article New Clinical Trial Aims to Create Bioresource for Improved Mesothelioma Diagnosis, now available on the Surviving Mesothelioma website. Tsim, S, et al, “Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study”, November 24, 2016, BMJ Open, http://bmjopen.bmj.com/content/6/11/e013324.full For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

Loading Respiratory Medicine collaborators
Loading Respiratory Medicine collaborators